FDA’s Gottlieb announces policy on stem cells

The US Food and Drug Administration has taken steps to curb the activities of unlicensed stem cell clinics while preparing for the roll-out in the autumn of a new regulatory framework for developers of cell and tissue-engineered products.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States